

**REMARKS**

Claims 151-218 are now pending. By the present amendment, eleven (11) claims are amended and 26 claims are added. No new matter is believed to be added and no change in inventorship results from the amendments proposed herein. The amendments proposed herein are made only to focus prosecution on various embodiments of the present invention and are made for reasons unrelated to patentability. No fees for additional claims are believed to be payable. Applicant expressly reserves the right to prosecute one or more cancelled claims in one or more continuing applications.

Support for amended claims 151, 157-159, 167, 172 and 187-191 and new claims 193-218 can be found throughout the original disclosure, for example, the specification, examples and claims as originally filed. Specific examples of support are provided below.


Claim No.	Exemplary Support
151	Page 13, lines 13-22; page 25, lines 14-16; page 28, line 25 – page 29, line 6; page 31, lines 8-10; page 39, lines 19-24; page 40, lines 5-14; and Tables 9-12 and Table 13, Period 2
157	Page 20, line 16 – page 21, line 12
158	Page 20, line 16 – page 21, line 12
159	Page 20, line 16 – page 21, line 12
167	Page 47, line 19
172	Page 133, lines 13-18
187	Page 28, line 25 – page 29 line 6; and Tables 9-12, Patient Nos.: 1,2,3,4,5,8,10,11,17
188	Page 109, line 5 – page 110, line 5; and Tables 9-12, Patient Nos.: 2,3,4,5,7,8,10,11,13,14,15,17 Table 13, Period 2, Sub. Nos.: 1,2,3,4,5,6,7,8,9,10
189	Page 28, line 25 – page 29 line 6; and Tables 9-12, Patient Nos.: 1,2,3,4,5,7,8,10,11,13,14,15,17 Table 13, Period 2, Sub. Nos.: 1,3,5,7,8,9,10
190	Page 20, lines 9-12;

Claim No.	Exemplary Support
	Tables 9-12, Patient Nos.: 2,3,4,5,7,8,10,13,17; and Table 13, Period 2, Sub. Nos.: 1,3,4,5,7,8,9,10
191	Page 19, lines 24-27
192	Page 20, lines 5-8
193	Table 9, page 98 and 99
194	Table 10, Patients 7, 8, 13 Table 12, Patient 17
195	Table 9-12, Patients 2, 6, 7, 11, 13, 15, 17
196	Table 9-12, Patient 2, 6, 8, 11, 15, 17
197	Table 13, Period 2
198	Tables 9-12, Patients 4, 7, 8, 11, 13, 17 Table 13, Period 2, Sub. Nos. 2, 3, 4, 5, 7, 8, 9, 10
199	Page 28, line 25 – page 29, line 6
200	Page 28, line 25 – page 29, line 6
201	Tables 9-12, Patients 2, 7, 8, 11, 13, 17 Table 13, Period 2, Sub. Nos. 2, 3, 4, 5, 7, 8, 9, 10
202	Tables 9-12, Patient #s:

Claim No.	Exemplary Support
	1,2,4,7,8,13,17; Table 13, Sub. Nos.: 1,3,5,7,9,10
203	Tables 9-12, Patient #s: 2,7,13,17 Table 13, Sub. Nos.: 5,7,9,10
204	Tables 9-12 (average plasma concentration at 20 minutes)
205	Tables 9-12, Patient #s: 2,4,13,17 Table 13, Sub. Nos.: 2,3,4,5,7,8,9
206	Tables 9-12
207	Tables 9-12 (average plasma concentration at 30 minutes)
208	Table 13, Period 2 (average plasma concentration at 30 minutes)
209	Tables 9-12 (average plasma concentration at 15 minutes)
210	Table 13, Period 2 (average $C_{max}$ )
211	Page 13, lines 13-22; page 25, lines 14-27; page 28, line 25 – page 29, line 6; page 31, lines 8- 10; page 39, lines 19-24; page 40, lines 5-14; and Tables 9-12 (average plasma concentration at 30 minutes).
212	Page 20, line 16 – page 21, line 12
213	Page 31, line 13.
214	Page 31, line 13.
215	Tables 9-11, Patients 2, 6, 11, 15
216	Table 13, Period 2
217	Page 28, line 25 – page 29, line 6
218	Page 28, line 25 – page 29, line 6

It is requested that the above proposed amendments be entered and that the claims be examined on the merits. Early and favorable consideration is requested. Should any questions arise, the Patent and Trademark Office is invited to telephone the undersigned.

Respectfully submitted,



David B. Fournier  
(Reg. No. 51,696)

**CUSTOMER NUMBER 26565**  
**MAYER, BROWN, ROWE & MAW LLP**  
P.O. Box 2828  
Chicago, IL 60609-2828  
Telephone: (312) 701-8034  
Facsimile: (312) 706-9000